Fluence and BioLumic Partner to Bring Advanced UV Light Treatments to Global Cultivation Facilities
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its exclusive partnership with BioLumic, a plant-growth biotechnology company that harnesses the power of ultraviolet (UV) light to sustainably increase plant yields, health and quality with Light Signal Recipes™. Under the agreement, Fluence and BioLumic will collaborate to deliver BioLumic’s cutting-edge UV Light Signals through Fluence’s industry-leading LED lighting solutions.
BioLumic’s patented technology leverages UV photomorphogenesis to trigger biological events in seeds and young plants to dramatically optimize plant performance. The company’s proven UV Light Signal Recipes™ can induce large gains in plant yields, desirable plant traits and vigor while also activating natural plant resistance to disease and pests.
“Our goal at Fluence is to drive cutting-edge plant science and innovations in agriculture technology,” said David Cohen, CEO of Fluence. “We’re excited to pursue that goal in collaboration with BioLumic and create the next generation of leading lighting solutions for cannabis and produce growers around the world.”
Fluence’s lighting systems will deliver BioLumic’s dynamic UV light treatments in the propagation phase of plant production—one-time treatments that trigger benefits that accrue through the entire plant growth cycle. Pairing BioLumic and Fluence’s leading market solutions enables cultivators to achieve high-quality yield gains, enhance cannabinoid levels and improve overall plant quality while reducing cycle-to-cycle variability.
“BioLumic’s Light Signal Recipes™ allow cultivators to fully and frictionlessly harness UV lighting to improve plant growth and genetic expression without big input costs or chemicals,” said Steve Sibulkin, CEO of BioLumic. “This partnership will accelerate the development of BioLumic’s Light Signal Platform, increase our company’s access to the global horticulture market and strengthen Fluence’s horticultural lighting portfolio. It’s a tremendous win for growers looking for new ways to grow more with less.”
The partnership reinforces Fluence’s deep history of science-led innovation in photobiology and follows several product launches this year, including RAPTR, RAZR Modular System, VYNE, SPYDR Fang, SPYDR 2h and Wireless Flex Dimming. Fluence’s dynamic and expanding suite of luminaires and lighting controls empowers growers with advanced lighting technology that meets and exceeds cultivation goals.
Fluence and BioLumic will initially work with select cannabis cultivation partners while industrializing commercial delivery systems for UV light that enhance Fluence’s end-to-end product offering in 2023. For more information about BioLumic, please visit www.biolumic.com. For more information about Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
About BioLumic
BioLumic is an agricultural biotech company that programs plants with light to unlock growth, quality and disease-resistance. The company's Light Signal Recipe™ platform combines biological insights and genetic marker knowledge to mediate genetic expression with a one-time application of light signals. These treatments are scalable and require no chemical application, genetic modification, facility expansion or large input costs. BioLumic has worked with 12 crops, including cannabis, soybeans, corn, leafy greens and strawberries. In cannabis, the company has helped cultivators produce large double-digit gains in dry flower yield, THC concentration, minor cannabinoids and terpene expression. To learn more, visit www.biolumic.com or send an email to info@biolumic.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005019/en/
Contact information
For Fluence,
Nichole Hazard
fluence@redfancommunications.com
C: 512-960-7656
For BioLumic,
Trace Stevens
media@biolumic.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 23:06:00 EEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom